5% stakes
Vestal Point Capital
Institution
- 5% stake reports
- 42
- 5% stake stocks
- 21
- Latest report
- 26/08/14
5% stake reports
| Stock | ||
|---|---|---|
| Monte Rosa Therapeutics GLUE08/14 | 5.4%4,600,000 sh | First report |
| Myriad Genetics MYGN08/14 | 6.1%5,735,000 sh | First report |
| Solid Biosciences SLDB08/14 | 4.8%4,833,796 sh | −2.7pp |
| Immunocore Holdings IMCR08/14 | 3.5%1,800,000 sh | −2.0pp |
| Nurix Therapeutics NRIX08/14 | 7.8%8,050,000 sh | +1.5pp |
| Alto Neuroscience ANRO08/14 | 2.2%785,000 sh | −4.3pp |
| iBio08/14 | 7.9%4,025,000 sh | −2.0pp |
| Taysha Gene Therapies TSHA05/15 | 6.3%18,000,000 sh | +1.3pp |
| Bicara Therapeutics BCAX05/15 | 8.3%5,425,000 sh | +1.8pp |
| Enliven Therapeutics ELVN05/15 | 5.4%3,250,000 sh | −1.1pp |
| Alto Neuroscience ANRO05/15 | 6.5%2,064,075 sh | −1.5pp |
| Immatics IMTX05/15 | 4.6%6,175,000 sh | −0.7pp |
| Bright Minds Biosciences DRUG05/15 | 5%492,319 sh | First report |
| Nurix Therapeutics NRIX05/15 | 6.3%6,500,000 sh | First report |
| Aprea Therapeutics APRE05/15 | 9.9%22,654,832 sh | First report |
| Immunocore Holdings IMCR05/15 | 5.5%2,766,868 sh | First report |
| Bicara Therapeutics BCAX02/17 | 6.5%3,575,000 sh | −2.7pp |
| Solid Biosciences SLDB02/17 | 7.5%5,815,000 sh | +5.2pp |
| Taysha Gene Therapies TSHA02/17 | 5%13,750,000 sh | First report |
| Enliven Therapeutics ELVN02/17 | 6.5%3,830,000 sh | First report |
